Search Results
CAR-T vs bispecifics in triple-class refractory multiple myeloma: comparing outcomes & sequencing
Linvoseltamab versus teclistamab for TCE RRMM and the sequencing of bispecifics with CAR-Ts
Hitting the BCMA Target in Multiple Myeloma
Sequencing BCMA Myeloma Therapies
Episode 1 - Conversations in Relapsed/Refractory Multiple Myeloma
An analysis of survival outcomes in patients with triple-class refractory myeloma
Coordinating Better Outcomes in Multiple Myeloma
Updates on CAR-T and BCMA Antibodies in Multiple Myeloma
Optimising the management of multiple myeloma in the early relapsed/refractory setting
Bispecific Antibodies in Multiple Myeloma | Dana-Farber Cancer Institute
BMS-986393, a novel anti-GPRC5D CAR-T cell therapy, in multiple myeloma
Management of R/R myeloma including CAR-T and Bispecifics
